medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast cancer local recurrence after breast-conserving surgery, making them good candidates for adjuvant radiotherapy omission, suggests the LUMINA study.
LUMINA efficacy presentation from ASCO 2022, Chicago
MonarchE efficacy presentation from ESMO Breast Cancer 2022, Berlin
medwireNews: Two subgroup analyses from the monarchE study confirm the benefit of supplementing adjuvant endocrine therapy (ET) with the CDK4/6 inhibitor abemaciclib in people with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence.
medwireNews: A single dose of patritumab deruxtecan (HER3-DXd) elicits a “clinically meaningful” response in previously untreated patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, the SOLTI TOT-HER3 investigators have found.
medwireNews: Using the 21-gene recurrence score (RS) in conjunction with response to preoperative endocrine therapy (ET) could help to spare adjuvant chemotherapy in certain pre- and postmenopausal patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, suggest findings from the WSG-ADAPT umbrella trial.
